Marshall Wace LLP Cuts Stock Position in LivaNova PLC (NASDAQ:LIVN)

Marshall Wace LLP trimmed its position in shares of LivaNova PLC (NASDAQ:LIVN) by 31.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 486,638 shares of the company’s stock after selling 225,194 shares during the period. Marshall Wace LLP owned about 0.90% of LivaNova worth $26,677,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Norges Bank acquired a new position in LivaNova in the fourth quarter valued at $26,064,000. Great Lakes Advisors LLC purchased a new stake in shares of LivaNova in the 2nd quarter worth about $16,614,000. Mesirow Institutional Investment Management Inc. acquired a new stake in shares of LivaNova in the first quarter valued at approximately $13,816,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in LivaNova during the 4th quarter worth about $8,330,000. Finally, Magnetar Financial LLC lifted its stake in shares of LivaNova by 24.5% during the 1st quarter. Magnetar Financial LLC now owns 753,338 shares of the company’s stock worth $42,142,000 after purchasing an additional 148,178 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Stock Up 1.1 %

Shares of NASDAQ:LIVN opened at $52.31 on Friday. The firm has a market cap of $2.84 billion, a P/E ratio of -87.18 and a beta of 1.00. The company has a quick ratio of 2.94, a current ratio of 3.45 and a debt-to-equity ratio of 0.49. The company’s 50-day moving average price is $48.73 and its two-hundred day moving average price is $53.33. LivaNova PLC has a 12 month low of $42.75 and a 12 month high of $64.47.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.15. The company had revenue of $318.60 million during the quarter, compared to the consensus estimate of $305.05 million. LivaNova had a positive return on equity of 13.77% and a negative net margin of 1.37%. As a group, research analysts forecast that LivaNova PLC will post 2.58 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

LIVN has been the topic of a number of recent research reports. Robert W. Baird raised shares of LivaNova from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $55.00 to $66.00 in a research report on Tuesday, September 17th. Baird R W upgraded LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 17th. Needham & Company LLC upped their price objective on LivaNova from $72.00 to $75.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Finally, Stifel Nicolaus raised their price target on shares of LivaNova from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, LivaNova has a consensus rating of “Buy” and a consensus target price of $70.80.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.